MX12213A - Metodo de preparacion de dihidrato de azitromicina cristalino - Google Patents

Metodo de preparacion de dihidrato de azitromicina cristalino

Info

Publication number
MX12213A
MX12213A MX1221388A MX1221388A MX12213A MX 12213 A MX12213 A MX 12213A MX 1221388 A MX1221388 A MX 1221388A MX 1221388 A MX1221388 A MX 1221388A MX 12213 A MX12213 A MX 12213A
Authority
MX
Mexico
Prior art keywords
azythromycin
dihydrate
crystalline
preparation
crystalline azythromycin
Prior art date
Application number
MX1221388A
Other languages
English (en)
Spanish (es)
Inventor
Douglas John Meldrum Allen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22202456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX12213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX12213A publication Critical patent/MX12213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX1221388A 1987-07-09 1987-07-09 Metodo de preparacion de dihidrato de azitromicina cristalino MX12213A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1987/001612 WO1989000576A1 (en) 1987-07-09 1987-07-09 Azithromycin dihydrate

Publications (1)

Publication Number Publication Date
MX12213A true MX12213A (es) 1993-05-01

Family

ID=22202456

Family Applications (1)

Application Number Title Priority Date Filing Date
MX1221388A MX12213A (es) 1987-07-09 1987-07-09 Metodo de preparacion de dihidrato de azitromicina cristalino

Country Status (45)

Country Link
US (1) US6268489B1 (en, 2012)
EP (1) EP0298650B1 (en, 2012)
JP (1) JPH0631300B2 (en, 2012)
KR (1) KR900006218B1 (en, 2012)
CN (1) CN1016785B (en, 2012)
AP (1) AP44A (en, 2012)
AR (1) AR243532A1 (en, 2012)
AT (1) ATE72446T1 (en, 2012)
AU (1) AU604553B2 (en, 2012)
BA (1) BA98213B1 (en, 2012)
BG (1) BG47348A3 (en, 2012)
CA (1) CA1314876C (en, 2012)
CS (1) CS272241B2 (en, 2012)
CY (1) CY1776A (en, 2012)
DD (1) DD271705A5 (en, 2012)
DE (1) DE3868296D1 (en, 2012)
DK (1) DK172573B1 (en, 2012)
EG (1) EG18527A (en, 2012)
ES (1) ES2038756T3 (en, 2012)
FI (1) FI91263C (en, 2012)
GR (1) GR3003737T3 (en, 2012)
HK (1) HK127594A (en, 2012)
HU (1) HU211862A9 (en, 2012)
IE (1) IE60354B1 (en, 2012)
IL (1) IL86979A (en, 2012)
IN (1) IN168879B (en, 2012)
IS (1) IS1540B (en, 2012)
LV (1) LV10624B (en, 2012)
MA (1) MA21323A1 (en, 2012)
MX (1) MX12213A (en, 2012)
MY (1) MY103744A (en, 2012)
NO (1) NO171556C (en, 2012)
NZ (1) NZ225338A (en, 2012)
OA (1) OA08743A (en, 2012)
PH (1) PH30953A (en, 2012)
PL (1) PL157145B1 (en, 2012)
PT (1) PT87933B (en, 2012)
RO (1) RO107257B1 (en, 2012)
RU (1) RU2066324C1 (en, 2012)
SG (1) SG27794G (en, 2012)
SI (1) SI8811325A8 (en, 2012)
UA (1) UA27040C2 (en, 2012)
WO (1) WO1989000576A1 (en, 2012)
YU (1) YU45075B (en, 2012)
ZA (1) ZA884925B (en, 2012)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
US5912331A (en) * 1991-03-15 1999-06-15 Merck & Co., Inc. Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
US5985844A (en) * 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5189159A (en) * 1992-04-02 1993-02-23 Merck & Co., Inc. 8a-AZA-8a-homoerythromycin cyclic iminoethers
CA2081268A1 (en) * 1991-10-25 1993-04-26 Katsuhiro Imaki Glycine derivative monosodium salt tetrahydrate
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
US5210235A (en) * 1992-08-26 1993-05-11 Merck & Co., Inc. Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics
US5332807A (en) * 1993-04-14 1994-07-26 Merck & Co., Inc. Process of producing 8A- and 9A-azalide antibiotics
CN1034734C (zh) * 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
WO1995030422A1 (en) 1994-05-06 1995-11-16 Pfizer Inc. Controlled-release dosage forms of azithromycin
ES2122905B1 (es) * 1996-07-11 1999-11-16 Astur Pharma Sa Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
EE04681B1 (et) * 1997-10-16 2006-08-15 PLIVA, farmaceutska industrija, dionicko dru�tvo 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
PT102130A (pt) * 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
DE69921192T2 (de) 1998-11-30 2006-02-16 Teva Pharmaceutical Industries Ltd. Ethanolate des azithromycin, herstllungsverfahren und deren pharmazeutische zusammenstellungen
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
NZ514765A (en) * 1999-05-18 2004-05-28 Pfizer Prod Inc Novel crystalline forms of a macrolide antibiotic
ATE334136T1 (de) 1999-06-29 2006-08-15 Sandoz Ag Verfahren zur herstellung von azithromycin
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
WO2001049697A1 (en) * 2000-01-04 2001-07-12 Teva Pharmaceutical Industries Ltd. Preparation method of azithromycin dihydrate
ES2162764B1 (es) * 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
AU2000270425A1 (en) 2000-07-25 2002-02-13 Instituto De Investigacion En Quimica Aplicada S.C Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydr oxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-ona and obtaining a new form of 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin
ES2172417B1 (es) * 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
JP2004506664A (ja) * 2000-08-23 2004-03-04 ウォックハート・リミテッド 無水アジトロマイシンの製造法
RU2279439C2 (ru) * 2000-11-27 2006-07-10 Сандоз Аг Азитромицин в форме моногидрата и способ его получения
SK287814B6 (sk) * 2000-11-27 2011-11-04 Sandoz Ag Azithromycin in the form of a monohydrate, a process for its preparation and pharmaceutical compositions comprising same
IN190080B (en, 2012) * 2001-01-29 2003-06-07 Alembic Ltd
KR100491183B1 (ko) 2001-03-21 2005-05-25 한미약품 주식회사 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
MXPA03010028A (es) 2001-05-22 2004-02-12 Pfizer Prod Inc Formas cristalinas de azitromicina.
EP1671979B1 (en) 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
YU8804A (sh) * 2001-08-21 2006-08-17 Pfizer Products Inc. Jedno-dozni azitromicin
PL371259A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Directly compressible formulations of azithromycin
IL161259A0 (en) * 2001-12-21 2004-09-27 Pfizer Prod Inc Methods for wet granulating azithromycin
RU2283092C2 (ru) * 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
US7376064B2 (en) 2002-02-25 2008-05-20 Samsung Electronics Co., Ltd. Method and apparatus for recording data on optical recording medium
ITMI20021209A1 (it) * 2002-06-04 2003-12-04 Chemi Spa Processo di preparazione di azitromicina ad elevata purezza
US6855813B2 (en) * 2002-07-19 2005-02-15 Alembic Limited Process for the preparation of azithromycin monohydrate
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
GB2395482A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Process for preparing non-hygroscopic azithromycin dihydrate
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
KR20060109481A (ko) * 2003-12-04 2006-10-20 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CN1889932A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 制备药用多颗粒的方法
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
RU2260012C1 (ru) * 2004-01-29 2005-09-10 Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" Способ кристаллизации азитромицина дигидрата
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2006011160A1 (en) 2004-06-28 2006-02-02 Alembic Limited Process for the preparation of azithromycin monohydrate isopropanol clathrate
CN1308361C (zh) * 2004-08-09 2007-04-04 大连振邦氟涂料股份有限公司 乙烯－三氟氯乙烯共聚物的制备方法
US7683162B2 (en) * 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
TW200631955A (en) * 2004-12-01 2006-09-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Non-hygroscopic and powdery amorphous pimecrolimus
CA2591923A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CN100366686C (zh) * 2006-01-12 2008-02-06 济南瑞氟化工科技有限公司 一种氟硅超双疏不粘涂料
CA2654450A1 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
US7704959B2 (en) 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
US20090062220A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched azithromycin
CN101177441B (zh) * 2007-12-05 2012-05-23 浙江耐司康药业有限公司 一种稳定的阿奇霉素一水合物结晶的制备方法
CN101624412B (zh) * 2008-07-10 2012-07-04 刘力 大环内酯类衍生物及其制备和用途
HRP20201150T8 (hr) 2008-10-07 2021-06-25 Horizon Orphan Llc Inhalacija levofloksacina za smanjenje upale pluća
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
CN101418026B (zh) * 2008-10-09 2011-05-18 南京工业大学 一种晶型和粒度可控的阿奇霉素结晶工艺
CN101787063B (zh) * 2009-01-23 2012-12-19 刘力 抗感染药物及其制备和用途
EP2405909A1 (en) 2009-03-13 2012-01-18 Da Volterra Compositions and methods for elimination of gram-negative bacteria
CA2938650C (en) 2009-09-04 2018-01-09 Raptor Pharmaceuticals Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
CN102911219A (zh) * 2011-08-03 2013-02-06 山东方明药业集团股份有限公司 一种阿齐霉素在水相直接结晶的方法
CN103159811A (zh) * 2011-12-10 2013-06-19 山东方明药业集团股份有限公司 一种阿齐霉素中间体9a-脱氧-9a-氮杂-9a-高红霉素A的制备方法
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
CN102417531B (zh) * 2011-12-20 2014-06-11 浙江国邦药业有限公司 一种阿奇霉素一水合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020270A (en) * 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
US4219641A (en) * 1979-06-14 1980-08-26 The Upjohn Company Process for preparing erythromycin succinate
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4526889A (en) * 1982-11-15 1985-07-02 Pfizer Inc. Epimeric azahomoerythromycin A derivative, intermediates and method of use
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
YU43402B (en) * 1985-03-04 1989-06-30 Pliva Pharm & Chem Works Process for preparation of 11-aza-10-deoxo-10-dihydroeritromycin "a" by using electro-chemical reduction
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents

Also Published As

Publication number Publication date
IL86979A (en) 1992-11-15
CN1030422A (zh) 1989-01-18
EP0298650A3 (en) 1989-11-08
EP0298650B1 (en) 1992-02-05
MY103744A (en) 1993-09-30
AP44A (en) 1989-07-27
JPH0631300B2 (ja) 1994-04-27
BG47348A3 (bg) 1990-06-15
AR243532A1 (es) 1993-08-31
IE60354B1 (en) 1994-06-29
ZA884925B (en) 1990-02-28
FI91263B (fi) 1994-02-28
FI900087L (fi) 1990-01-08
DE3868296D1 (de) 1992-03-19
EP0298650A2 (en) 1989-01-11
DK172573B1 (da) 1999-01-25
LV10624B (en) 1995-10-20
IN168879B (en, 2012) 1991-06-29
PT87933A (pt) 1989-06-30
PL273590A1 (en) 1989-03-20
IE882108L (en) 1989-01-09
FI91263C (fi) 1994-06-10
KR900006218B1 (ko) 1990-08-25
PH30953A (en) 1997-12-23
RU2066324C1 (ru) 1996-09-10
IS3370A7 (is) 1989-01-10
GR3003737T3 (en, 2012) 1993-03-16
AU1883988A (en) 1989-01-12
CN1016785B (zh) 1992-05-27
HU211862A9 (en) 1995-12-28
PT87933B (pt) 1994-09-30
AP8800093A0 (en) 1988-05-01
AU604553B2 (en) 1990-12-20
ATE72446T1 (de) 1992-02-15
JPS6438096A (en) 1989-02-08
CA1314876C (en) 1993-03-23
UA27040C2 (uk) 2000-02-28
FI900087A0 (fi) 1990-01-08
MA21323A1 (fr) 1989-04-01
RO107257B1 (ro) 1993-10-30
NO900077L (no) 1990-01-08
HK127594A (en) 1994-11-25
NO171556B (no) 1992-12-21
WO1989000576A1 (en) 1989-01-26
YU45075B (en) 1991-08-31
CY1776A (en) 1995-10-20
ES2038756T3 (es) 1993-08-01
DD271705A5 (de) 1989-09-13
US6268489B1 (en) 2001-07-31
YU132588A (en) 1990-02-28
IL86979A0 (en) 1988-12-30
BA98213B1 (bs) 1999-08-02
DK380688D0 (da) 1988-07-08
CS489688A2 (en) 1990-03-14
CS272241B2 (en) 1991-01-15
DK380688A (da) 1989-01-10
SI8811325A8 (en) 1996-12-31
NO171556C (no) 1993-03-31
IS1540B (is) 1994-01-28
KR890002137A (ko) 1989-04-08
OA08743A (fr) 1989-03-31
PL157145B1 (en) 1992-04-30
LV10624A (lv) 1995-04-20
EG18527A (en) 1993-10-30
NZ225338A (en) 1990-02-26
NO900077D0 (no) 1990-01-08
SG27794G (en) 1994-10-14

Similar Documents

Publication Publication Date Title
MX12213A (es) Metodo de preparacion de dihidrato de azitromicina cristalino
FI893100L (fi) Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi
GR880100512A (en) Preparation method of 4-ammonium derivatives of epipodophyllotoxinc glucosite
FI875660L (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi
FI875024A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 1-alkyyli-6-halogeenitetrahydronaftaleenijohdannaisten valmistamiseksi
FI873467A7 (fi) Menetelmä 5-amino-4-hydroksivaleriaanahappojohdannaisten valmistamiseksi
PT86800A (pt) Process for the preparation of erythromycin derivatives
FI884553A7 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 9-aminotetrahydroakridiinijohdannaisten valmistamiseksi
PT87153A (pt) Process for the preparation of acid ribofuranuronic derivatives
PT87698A (pt) Procede de preparation de derives de n-phenylpyrazole
FI884984A7 (fi) Menetelmä metyylitritioyhdisteiden kohdennettujen johdannaisten valmistamiseksi
PL274216A1 (en) Method of manufacture of derivatives of imidazepiridazine
PT87854A (pt) Process for the preparation of thio-urea derivatives
FI880842A0 (fi) Menetelmä kiteisen kefeemisulfaatin valmistamiseksi
BR8701786A (pt) Preparacao de halogenetos de arila
ES551480A0 (es) Metodo de obtencion de derivados iminotiazolidinicos
FI883803L (fi) Natriumpuriinien valmistusmenetelmä
FI891191A7 (fi) Menetelmä 3-eksometyleeni-kefam-johdannaisten valmistamiseksi
GB2190081B (en) Method of manufacturing moranoline derivatives
FI873388L (fi) Menetelmä leivonnaisen valmistamiseksi
IT8848410A0 (it) Procedimento per la preparazione di calcestruzzo proiettato
PT88465A (pt) Process for the preparation of macrolide compounds
PT88467A (pt) Process for the preparation of macrolide compounds
GB2189243B (en) Method of manufacturing moranoline derivatives
ES557310A0 (es) Metodo de preparacion de derivados fluouracilicos